Markets

Novavax Starts Phase 2 Coronavirus Vaccine Clinical Trial

Novavax (NASDAQ: NVAX) is behind the leaders in the race to develop a coronavirus vaccine to prevent COVID-19, but the biotech continues to trot along. On the heels of positive phase 1 data earlier this month, the biotech started the phase 2 portion of its phase 1/2 clinical trial testing its coronavirus vaccine NVX-CoV2373.

The new study will enroll up to 1,500 subjects, substantially more than the 131 subjects enrolled in the phase 1 study. The phase 2 portion also expands the potential ages of participants from a range of 18 to 59 in phase 1 to a range of 18 to 84 for the phase 2 study.

Since older adults are especially vulnerable if they catch COVID-19, its important for a vaccine to be both safe and able to generate an immune response in the older adults. To get the answer quickly, Novavax plans to enroll half of the clinical trial with older adults, aged 60 to 84.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently demonstrated that their coronavirus vaccine, BNT162b2, was able to generate antibodies in older adults 65 to 85. The levels weren't as high as younger subjects, but the antibody levels were still higher than levels seen in patients who had recovered from COVID-19.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Novavax's investors will have to wait until the fourth quarter for interim data on antibody levels and safety of the vaccine from the phase 2 study. That's around the same time Pfizer and BioNTech, AstraZeneca, and Moderna expect to have initial phase 3 data, putting Novavax a few months behind the current leaders.

How much Novavax's slower pace hurts the biotech will ultimately be determined by the safety and efficacy of all the vaccines, as well as how quickly the front-runners can ramp up manufacturing to meet global demand.

10 stocks we like better than Novavax
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 1, 2020

 

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVAX PFE BNTX

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More